Asco-GU – Bicycle tries to put distance between itself and Seagen
However, results with BT8009, one of several datasets being presented this week at the Asco-GU conference, fail to convince many investors.
Go or no go? Lecanemab’s destiny approaches
2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.
Ash 2022 – Affimed feels the pain
Affimed investors find that what goes up must come down, though the stock owes only part of its fall to an Ash presentation.
SITC 2022 preview – cytokines and oral checkpoints
Recently unveiled abstract titles for next month's SITC conference reveal new competition for Incyte’s small-molecule PD-L1 inhibitors.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
